Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482949 | 0.79 | IGF1R (0.47) | CA1CA2CA4CA6CHEK1 | |
| SCHEMBL7929970 | 0.78 | TTR (0.56) | CHEK1DAPK3RETPDGFRBPIM1 | |
| SCHEMBL282136 | 0.78 | CYP3A4 (0.56) | CA1CA2CA4CA6CYP3A4 | |
| SCHEMBL9321667 | 0.77 | CYP3A4 (0.37) | CA1CA2CA4CA6TTR | |
| SCHEMBL4935468 | 0.77 | CYP3A4 (0.58) | CA1CA2CA4CA6CHEK1 | |
| SCHEMBL10824723 | 0.75 | TSHR (0.42) | CA1CA2CA4CA6CYP3A4 | |
| SCHEMBL20973548 | 0.75 | ERN1 (0.46) | CA1CA2CA4CA6CYP3A4 | |
| SCHEMBL22400411 | 0.75 | NOTUM (0.35) | NOTUMMEN1KMT2A | |
| SCHEMBL30688789 | 0.75 | NOTUM (0.35) | NOTUMMEN1KMT2A | |
| SCHEMBL26341394 | 0.75 | ADRB2 (0.31) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-2411352-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBVIE INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES | 2016-12-22 | — | — | US | disclosed |
| CN-105924386-A | Antiviral Compounds And Uses Thereof | ABBVIE 公司 | 2016-09-07 | — | — | CN | disclosed |
| EP-2639226-B1 | Anti-infective pyrimidines and uses thereof | ABBVIE BAHAMAS LTD (BS) | 2016-08-31 | — | — | EP | disclosed |
| US-9353091-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9139536-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9095590-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | ABBVIE INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2368882-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2203431-B1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LAB (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | US | disclosed |
| CN-101842360-A | Anti-infective pyrimidines and uses thereof | ABBOTT LAB | 2010-09-22 | — | — | CN | disclosed |
| EP-2222646-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| CN-101801935-A | Uracil or thymine derivatives for the treatment of hepatitis C | ABBOTT LAB | 2010-08-11 | — | — | CN | disclosed |
| EP-2203431-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | Abbott Laboratories (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039127-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | CA1 2881/4885CA2 1429/4885CA4 1762/4885 |
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | CA1 3987/4885CA2 3738/4885CA4 2966/4885 |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | MAVS, ZC3HAV1, EIF2AK2 | CA1 3987/4885CA2 3738/4885CA4 2966/4885 |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | CA1 2881/4885CA2 1429/4885CA4 1762/4885 |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CA1 2881/4885CA2 1429/4885CA4 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.